Table 3.
MN antibody response against heterologous strain NIBRG14
| HA dose | No. of subjects | MN antibody response based on: |
||
|---|---|---|---|---|
| Seroconversiona | Geometric mean increaseb | Seroprotectionc | ||
| 7.5 μg | 40 | 14 (35; 22.1–50.5) | 2.8 (1.9–4.2) | 11 (27.5; 14.6–43.9) |
| 15 μg | 40 | 21 (52.5; (37.5–67.1) | 4.1 (2.8–6.3) | 16 (40; 24.9–56.7) |
a
Seroconversion was defined as a ≥4-fold rise in antibody titer compared to the day zero titer. Data are the number of responders, with the percentage and 95% CI provided in parentheses.
b
The geometric mean increase (with 95% CI in parentheses) reflects the increase in the GMT.
c
Seroprotection is the number of volunteers whose titer was ≥1:40 (with the percentage of responders and the 95% CI shown in parentheses).